| Product Description |
Recombinant CHO-K1 cells stably overexpress human immunoglobulin gamma Fc region receptor II-a (FcγRIIa/CD32A 131Arg) on the surface. The surface expression of CD32A 131Arg is validated by FACS analysis. This stable cell line product is designed for measuring binding affinity and stability of Fc region of antibodies and Fc fusion proteins, or antibody based biologics binding with CD32A 131Arg. GenScript also offers CD32A 131His stable cell line (Cat. No. M00598) for FcγRIIa polymorphism study. |
| Applications |
Binding assay or use as immunogen for antibody development |
| Expressed Gene |
NCBI reference sequence NM_001136219.1 |
| Target Protein |
NP_001129691.1 |
| Host Cell |
CHO-K1 |
| Size |
Two vials of frozen cells (>1×106 per vial in 1 mL) |
| Storage |
Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received. |
| Mycoplasma Status |
Negative. The mycoplasma test was performed with MycoAlert™ PLUS Mycoplasma Detection Kit (Cat. No. LT07-318, Lonza). |
| Stability |
Stable through more than 15 passages without significant changes in assay performance or expression profile. |
| Culture Properties |
Adherent |
| Freeze Medium |
95% complete growth medium, 5% (V/V) DMSO (Cat. No. D2650, Sigma) |
| Complete Growth Medium |
Ham’s F-12K (Kaighn’s) (Cat. No. 21127-022, Life Technologies), 10% FBS (Cat. No. 10099-141, Life Technologies) |
| Culture Medium |
Ham’s F-12K (Kaighn’s), 10% FBS, 8 μg/ml Puromycin (Cat. No. A11138-03, Life Technologies) |
| Gene Synonyms |
CD32, CD32A, CDw32, FCG2, FCGR21, FcGR, FcgammaRIIa, IGFR2, FCGR2A |
| Background |
Human CD32 group consists of FcγRIIA, B and C proteins that share 94-99% amino acid identity in their extracellular domains but differ substantially in their transmembrane and cytoplasmic domains. CD32A, also known as FcγRIIA, is a surface receptor protein and part of a large population of B cell co-receptors. The protein is found on phagocytic cells such as macrophages and neutrophils, and it is involved in the process of phagocytosis and clearing of immune complexes. It has low-affinity for IgG antibodies and down-regulates antibody production in the presence of IgG. This feedback loop acts to lower the production of IgG by B cells when there is a surplus in the body. Therefore, targeting CD32A may represent an approach to immunotherapy of B-cell malignancies. |
Figure 1. FACS analysis of cell surface expression of CD32A 131Arg on CHO-K1/CD32A 131Arg cells. The CHO-K1/CD32A 131Arg cells (blue) and the negative control CHO-K1 cells (red) were probed using APC-conjugated Mouse Anti-Human CD32 antibody (Cat. No. 559769, BD Bioscience).
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
如您需要获取细胞系产品的说明书，请点击“Manual”，完善信息后点击“提交”。
我们会第一时间联系回复您。注意：中国地区购买的产品，说明书需要以中文站为准。
您也可拨打400-0258686转5810，或发邮件至product@genscript.com.cn联系我们。
更多产品文件类型 >>
